Department of Hematopathology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Arch Pathol Lab Med. 2010 Sep;134(9):1261-70. doi: 10.5858/2009-0350-RA.1.
Acute erythroid leukemia (AEL) is an uncommon type of acute myeloid leukemia (AML), representing less than 5% of all cases. Acute erythroid leukemia is characterized by a predominant erythroid proliferation, and in the current World Health Organization (WHO) classification scheme there are 2 subtypes: erythroleukemia (erythroid/myeloid leukemia) and pure erythroid leukemia. Morphologic findings are most important for establishing the diagnosis. The erythroleukemia subtype, which is most common, is defined as the presence of 50% or more erythroid precursors and 20% or more blasts in the nonerythroid component. The pure erythroid leukemia subtype is composed of 80% or more immature erythroblasts. Although these morphologic criteria appear straightforward, AEL overlaps with other types of AML and myelodysplastic syndrome that are erythroid rich.
To provide an update of AEL, including clinical presentation, morphologic features, immunophenotype, and cytogenetic and molecular data. As the erythroleukemia subtype is most common, the literature and this review are biased towards this subtype of AEL.
Clinicopathologic, cytogenetic, and molecular information were extracted from our review of pertinent literature and a subset of AEL cases in the files of The University of Texas M. D. Anderson Cancer Center (Houston) and University of South Alabama (Mobile).
The current WHO criteria for establishing the diagnosis of AEL reduce the frequency of this entity, as cases once classified as the erythroleukemia subtype are now reclassified as other types of AML, particularly AML with myelodysplasia-related changes and therapy-related AML. This reclassification also may have prognostic significance for patients with the erythroleukemia subtype of AEL. In contrast, the current WHO criteria appear to have little impact on the frequency and poor prognosis of patients with the pure erythroid leukemia subtype of AEL. Molecular studies, preferably using high-throughput methods, are needed for a better understanding of the pathogenesis of AEL, and for developing diagnostic and prognostic markers.
急性红细胞白血病(AEL)是一种罕见的急性髓系白血病(AML),占所有病例的不到 5%。急性红细胞白血病的特征是主要为红细胞增生,在目前的世界卫生组织(WHO)分类方案中有 2 个亚型:红白血病(红细胞/髓系白血病)和纯红细胞白血病。形态学发现对确立诊断最为重要。最常见的红白血病亚型定义为非红细胞成分中存在 50%或更多的红细胞前体和 20%或更多的原始细胞。纯红细胞白血病亚型由 80%或更多的未成熟红细胞组成。尽管这些形态学标准看起来很直接,但 AEL 与其他富含红细胞的 AML 和骨髓增生异常综合征重叠。
提供 AEL 的最新信息,包括临床表现、形态学特征、免疫表型以及细胞遗传学和分子数据。由于红白血病亚型最为常见,文献和本综述偏向于这种 AEL 亚型。
从我们对相关文献的综述以及德克萨斯大学 M. D. 安德森癌症中心(休斯顿)和南阿拉巴马大学(莫比尔)的 AEL 病例档案中提取了临床病理、细胞遗传学和分子信息。
目前 WHO 诊断 AEL 的标准降低了这种疾病的频率,因为曾经被归类为红白血病亚型的病例现在被重新归类为其他类型的 AML,特别是伴有骨髓增生异常相关改变和治疗相关的 AML。这种重新分类也可能对红白血病亚型的 AEL 患者具有预后意义。相比之下,目前的 WHO 标准似乎对纯红细胞白血病亚型的 AEL 患者的频率和预后不良影响不大。需要进行分子研究,最好使用高通量方法,以更好地了解 AEL 的发病机制,并开发诊断和预后标志物。